[HTML][HTML] Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
…, MM Horowitz, HJ Deeg, ME Horwitz - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT)
is unknown. We hypothesized that lower treatment-related mortality (TRM) with …
is unknown. We hypothesized that lower treatment-related mortality (TRM) with …
The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators
…, DW Kingma, ME Horwitz, E Mansfield… - Blood, The Journal …, 2000 - ashpublications.org
Familial Mediterranean fever (FMF) is a recessive disorder characterized by episodes of
fever and neutrophil-mediated serosal inflammation. We recently identified the gene causing …
fever and neutrophil-mediated serosal inflammation. We recently identified the gene causing …
[HTML][HTML] Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease
…, ED Warlick, MC Pasquini, ME Horwitz - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …
Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment
ME Horwitz, NJ Chao, DA Rizzieri… - The Journal of …, 2014 - Am Soc Clin Investig
BACKGROUND. Delayed hematopoietic recovery is a major drawback of umbilical cord
blood (UCB) transplantation. Transplantation of ex vivo–expanded UCB shortens time to …
blood (UCB) transplantation. Transplantation of ex vivo–expanded UCB shortens time to …
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell–depleted hematopoietic allograft
ME Horwitz, AJ Barrett, MR Brown… - … England Journal of …, 2001 - Mass Medical Soc
Background The treatment of chronic granulomatous disease with conventional allogeneic
hematopoietic stem-cell transplantation carries a high risk of serious complications and death…
hematopoietic stem-cell transplantation carries a high risk of serious complications and death…
[HTML][HTML] Prospective, randomized, double-blind, phase III clinical trial of anti–T-lymphocyte globulin to assess impact on chronic graft-versus-host disease–free survival …
RJ Soiffer, HT Kim, J McGuirk, ME Horwitz… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Several open-label randomized studies have suggested that in vivo T-cell
depletion with anti–T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) …
depletion with anti–T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) …
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial
…, ME Horwitz, C Karanes, E Leifer… - Blood, The Journal …, 2021 - ashpublications.org
Results of 2 parallel phase 2 trials of transplantation of unrelated umbilical cord blood (UCB)
or bone marrow (BM) from HLA-haploidentical relatives provided equipoise for direct …
or bone marrow (BM) from HLA-haploidentical relatives provided equipoise for direct …
Chronic graft-versus-host disease
ME Horwitz, KM Sullivan - Blood reviews, 2006 - Elsevier
Chronic graft versus host disease (GVHD) remains today one of the most vexing late
complications of allogeneic stem cell transplantation. Occurring a minimum of 100 days following …
complications of allogeneic stem cell transplantation. Occurring a minimum of 100 days following …
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study
ME Horwitz, PJ Stiff, C Cutler… - Blood, The Journal …, 2021 - ashpublications.org
Omidubicel is an ex vivo expanded hematopoietic progenitor cell and nonexpanded myeloid
and lymphoid cell product derived from a single umbilical cord blood unit. We report results …
and lymphoid cell product derived from a single umbilical cord blood unit. We report results …
[HTML][HTML] Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide
ME Horwitz, S Wease, B Blackwell… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
Purpose Increasing the number of hematopoietic stem and progenitor cells within an
umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB …
umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB …
